Transfusion-transmitted disease.
Many patients with haemophilia are infected with viruses, due to treatment with blood products--particularly from large pool clotting factor concentrates before 1985. AIDS in haemophilic patients was first described in 1982 and it has significantly reduced the life expectancy of these patients. Although no new sero-conversions have occurred since 1986, management of HIV in haemophilia remains a clinical challenge. Transfusion-associated hepatitis was recognized in 1943, and it is now an important complication of haemophilia treatment. Vaccination against HAV is recommended. Intensively-treated older haemophilic patients usually have serological evidence of HBV infection. HBV transmission has been stopped, but hepatitis B vaccination is still practised, because HDV requires HBV for propagation. Many patients are infected with HCV: before 1985 almost all patients who received clotting factor concentrate developed non-A, non-B hepatitis, now recognized as HCV. Treatment strategies are being developed for HCV in haemophilic patients. Parvo virus can be transmitted by clotting factor concentrate; it is very resistant to sterilization processes, transmission causing severe illness even in immuno-competent individuals. New blood-borne viruses responsible for sero-negative hepatitis include: GBV-A, B and C, and HGV. Although there is no link between CJD and haemophilia, there is concern about possible blood product transmission.
Lee
C A
CA
Haemophilia Centre & Haemostasis Unit, Royal Free Hospital NHS Trust, Hampstead, London, UK.
D001769:Blood / Q000821:virology; D001779:Blood Coagulation Factors / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D015897:Comorbidity; D007562:Creutzfeldt-Jakob Syndrome / Q000453:epidemiology / Q000635:transmission; D004340:Drug Contamination; D016731:Erythema Infectiosum / Q000453:epidemiology / Q000635:transmission; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000635:transmission; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000453:epidemiology / Q000601:surgery / Q000635:transmission; D006801:Humans; D008017:Life Expectancy; D008113:Liver Neoplasms / Q000209:etiology; D016031:Liver Transplantation; D016483:Lymphoma, AIDS-Related / Q000453:epidemiology; D016732:Parvovirus B19, Human; D011379:Prognosis; D015229:Sexually Transmitted Diseases, Viral / Q000453:epidemiology / Q000635:transmission; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000209:etiology; D065227:Transfusion Reaction; D014777:Virus Diseases / Q000635:transmission*; D015215:Zidovudine / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D015215:Zidovudine